Wang Li-Fei, Ma Jing-Xue, Liu Jian-Zong, Cai Su-Zhen, Lu Lan-Cun, Wang Zhen-Dong
The Second Hispital, Hebei Medical University, Shijiazhuang 050000, China.
Zhonghua Yan Ke Za Zhi. 2004 Jul;40(7):459-64.
To investigate the safety dosage of intravitreal injection of Plasmin, Hyaluronidase and their combination and to evaluate their efficacy in the formation of posterior vitreous detachment (PVD) through animal experiments.
Eight rabbits each were randomly assigned to one of six groups and one eye of each rabbit were experimental eye, the other is control eye. The position of drug injection was in posterior 1/3 of vitreous before papillary. The drug-injection groups were assigned as following: the first group-Hyaluronidase 20 IU (0.1 ml BSS), the second group-Hyaluronidase 30 IU (0.1 ml BSS), the third group-Plasmin 1 IU (0.1 ml BSS), the forth group-Plasmin 2 IU (0.1 ml BSS), the fifth group-Plasmin 3 IU (0.1 ml BSS), the sixth group- Hyaluronidase 20 IU (0.05 ml BSS) combined with Plasmin 1 IU (0.05 ml BSS); the control eyes were injected with BSS (0.1 ml) at the same position. The experimental rabbits were followed for 2 weeks, and in this period all eyes were examined with slit-lamp biomicroscopy, +90 D preset lens, indirect ophthalmoscope, electroretinography, B-scan, and optical coherence tomography. After two weeks, the animals were killed and the eyes enucleated. Scan electron and light microscopy were performed.
Hyaluronidase concentration of 20 IU, Plasmin concentration of 1 IU and their combination didn't produce inflammatory response and retinal toxicity in the experimental eyes. 30 IU Hyaluronidase and 2 IU Plasmin both caused mild inflammatory response in the vitreous without retinal histological changes, while the latter caused a reversible decrease in the ERG b-wave. 3 IU of Plasmin caused severe inflammatory response with retinal histological and electroretinographic changes. In safety dosage neither Hyaluronidase nor Plasmin alone were successful in producing completely posterior vitreous detachment (PVD), but the latter can produce partial PVD. The combination of Plasmin (1 IU) and Hyaluronidase (20 IU) was effective on producing completely PVD without retinal toxicity.
20 IU of Hyaluronidase and 1 IU of Plasmin are safe to retina and others structures in the eyes without any toxicity. Posterior vitreous injection of Hyaluronidase (20 IU) combined with Plasmin (1 IU) can produce complete posterior vitreous detachment.
通过动物实验研究玻璃体内注射纤溶酶、透明质酸酶及其联合用药的安全剂量,并评估它们在形成玻璃体后脱离(PVD)中的疗效。
将8只兔子随机分为6组,每组兔子的一只眼睛为实验眼,另一只为对照眼。药物注射部位为乳头前玻璃体的后1/3。药物注射组分配如下:第一组——透明质酸酶20 IU(0.1 ml平衡盐溶液),第二组——透明质酸酶30 IU(0.1 ml平衡盐溶液),第三组——纤溶酶1 IU(0.1 ml平衡盐溶液),第四组——纤溶酶2 IU(0.1 ml平衡盐溶液),第五组——纤溶酶3 IU(0.1 ml平衡盐溶液),第六组——透明质酸酶20 IU(0.05 ml平衡盐溶液)联合纤溶酶1 IU(0.05 ml平衡盐溶液);对照眼在相同位置注射平衡盐溶液(0.1 ml)。对实验兔子随访2周,在此期间所有眼睛均用裂隙灯生物显微镜、+90 D预置透镜、间接检眼镜、视网膜电图、B超扫描和光学相干断层扫描进行检查。2周后,处死动物并摘除眼球。进行扫描电子显微镜和光学显微镜检查。
20 IU的透明质酸酶、1 IU的纤溶酶及其联合用药在实验眼中未产生炎症反应和视网膜毒性。30 IU透明质酸酶和2 IU纤溶酶均在玻璃体中引起轻度炎症反应,无视网膜组织学改变,而后者导致视网膜电图b波可逆性降低。3 IU纤溶酶引起严重炎症反应,伴有视网膜组织学和视网膜电图改变。在安全剂量下,单独使用透明质酸酶或纤溶酶均未能成功产生完全性玻璃体后脱离(PVD),但后者可产生部分PVD。纤溶酶(1 IU)和透明质酸酶(20 IU)联合用药可有效产生完全性PVD,且无视网膜毒性。
20 IU透明质酸酶和1 IU纤溶酶对视网膜及眼内其他结构安全,无任何毒性。玻璃体内注射透明质酸酶(20 IU)联合纤溶酶(1 IU)可产生完全性玻璃体后脱离。